A new article from the Innovative Health Initiative (IHI) highlights how Europe is entering a new era in the fight against type 1 diabetes (T1D). At the heart of the article are clear policy recommendations developed by EDENT1FI and INNODIA – and we at DiaUnion strongly support their call to action.
At DiaUnion, our mission aligns directly with this vision: a future where T1D is no longer life-long, but preventable – and ultimately curable.
We focus on early detection as the essential first step that makes disease-modifying therapies possible. Without early detection, these breakthroughs cannot reach the people who need them most.
DiaUnion is proud to be part of EDENT1FI, the groundbreaking IHI project screening 200,000 children across Europe to identify risk before symptoms occur.
We also have deep roots in the former INNODIA research project, with our Project Director and several Principal Investigators having contributed to its scientific foundation – from biological research to clinical trial development.
The IHI article highlights how INNODIA built a pan-European clinical trial network, making Europe more attractive for the development of disease-modifying therapies and accelerating access for patients.
As Simone Overby Sloth, Danish Counsellor for Health to the EU, said during the recent T1D event at the European Parliament:
“The ecosystem of life sciences is the soil – it’s the foundation. We’re working hard to develop a better environment for cross-border clinical trials.”
DiaUnion, led by Medicon Valley Alliance, is proud to be part of that ecosystem – fostering public-private collaboration between hospitals, universities, industry, and policymakers in Denmark, Sweden, and beyond.
The road from research to real-world impact is long – but the policy recommendations make one thing clear: Early detection and strong public-private partnerships like DiaUnion are essential if we are to delay, prevent – and one day cure – type 1 diabetes.
